Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: A randomized, double-blind, placebo-controlled crossover trial

Journal of Infectious Diseases

Volumn 196, Issue 10, 2007, Pages 1500-1508

  Zuckerman, Richard A ^a   Lucchetti, Aldo ^d   Whittington, William L H ^b   Sánchez, Jorge ^d   Coombs, Robert W ^b   Zuñiga, Rosario ^d   Magaret, Amalia S ^b   Wald, Anna ^b,c   Corey, Lawrence ^b,c   Celum, Connie ^b,e  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d ASOCIACIÓN CIVIL IMPACTA SALUD Y EDUCACIÓN   (Peru)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VALACICLOVIR; ACICLOVIR; ANTIVIRUS AGENT; DRUG DERIVATIVE; VALINE; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM; SEROLOGY; VIRUS CONCENTRATION; VIRUS DETECTION; BLOOD; GENETICS; HERPES SIMPLEX; HOMOSEXUALITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ACYCLOVIR; ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CROSS-OVER STUDIES; DNA, VIRAL; DOUBLE-BLIND METHOD; HERPES SIMPLEX; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HIV-1; HOMOSEXUALITY, MALE; HUMANS; MALE; POLYMERASE CHAIN REACTION; RECTUM; RNA, VIRAL; TREATMENT OUTCOME; VALINE; VIRAL LOAD;

EID: 38449119047     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/522523     Document Type: Article

References (41)

1. Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004; 35:435-45.
2. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149-53.
3. Kreiss JK, Coombs R, Plummer F, et al. Isolation of human immunodeficiency virus from genital ulcers in Nairobi prostitutes. J Infect Dis 1989; 160:380-4.
4. Mbopi Keou FX, Gresenguet G, Mayaud P, et al. Genital herpes simplex virus type 2 shedding is increased in HIV-infected women in Africa. AIDS 1999; 13:536-7.
5. Schacker TW, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998; 280:61-6.
6. McClelland RS, Wang CC, Overbaugh J, et al. Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 2002; 16:2425-30.
7. Mosca J, Bednarik D, Raj N, et al. Herpes simplex virus type 1 can reactivate transcription of latent human immunodeficiency virus. Nature 1987; 325:67-70.
8. Margolis D, Ostrove J, Straus S. HSV-1 activation of HIV-1 transcription is augmented by a cellular protein that binds near the initiator element. Virology 1993; 192:370-4.
9. Kucera L, Leake E, Iyer N, Raben D, Myrvik Q. Human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 2 (HSV-2) can coinfect and simultaneously replicate in the same human CD4+ cell: effect of coinfection on infectious HSV-2 and HIV-1 replication. AIDS Res Hum Retroviruses 1990; 6:641-7.
10. Heng M, Heng S, Allen S. Coinfection and synergy of human immunodeficiency virus-1 and herpes simplex viurs-1. Lancet 1994; 343:255-8.
11. Moriuchi M, Moriuchi H, Williams R, Straus SE. Herpes simplex virus infection induces replication of human immunodeficiency virus type 1. Virology 2000; 278:534-40.
12. Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: a double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:21-8.
13. DeJesus E, Wald A, Warren T, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188:1009-16.
14. Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007; 356:790-9.
15. Ioannidis JPA, Collier AC, Cooper DA, et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 1998; 178:349-59.
16. Wald A, Zeh JE, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996; 124:8-15.
17. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital HSV-2 shedding in immunocompetent women. J Clin Invest 1997; 99: 1092-7.
18. Prince HE, Ernst CE, Hogrefe WR. Evaluation of an enzyme immunoassay system for measuring herpes simplex virus (HSV) type 1-specific and HSV type 2-specific IgG antibodies. J Clin Lab Anal 2000; 14:13-6.
19. Golden MR, Ashley-Morrow R, Swenson P, Hogrefe WR, Handsfield HH, Wald A. Herpes simplex virus type 2 (HSV-2) Western blot confirmatory testing among men testing positive for HSV-2 using the focus enzyme-linked immunosorbent assay in a sexually transmitted disease clinic. Sex Transm Dis 2005; 32:771-7.
20. Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (Immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 1988; 26:662-7.
21. Li CC, Seidel KD, Coombs RW, Frenkel LM. Detection and quantification of human immunodeficiency virus type 1 p24 antigen in dried whole blood and plasma on filter paper stored under various conditions. J Clin Microbiol 2005; 43:3901-5.
22. Jerome KR, Huang ML, Wald A, Selke S, Corey L. Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol 2002; 40:2609-11.
23. Wald A, Huang ML, Carrell D, Selke S, Corey L. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis 2003; 188:1345-51.
24. Limaye AP, Huang ML, Leisenring W, Stensland L, Corey L, Boeckh M. Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients. J Infect Dis 2001; 183:377-82.
25. Zuckerman RA, Whittington WL, Celum CL, et al. Higher concentration of HIV RNA in rectal mucosa secretions than in blood and seminal plasma, among men who have sex with men, independent of antiretroviral therapy. J Infect Dis 2004; 190:156-61.
26. Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997; 176:766-70.
27. Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002; 186:1718-25.
28. Freeman EE, Glynn JR. Factors affecting HIV concordancy in married couples in four African cities. AIDS 2004; 18:1715-21.
29. Ouedraogo A, Nagot N, Vergne L, et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 2006; 20:2305-13.
30. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
31. Rodriguez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 2006; 296:1498-506.
32. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996; 335:1091-8.
33. Rebbapragada A, Wachihi C, Pettengell C, et al. Negative mucosal synergy between herpes simplex type 2 and HIV in the female genital tract. AIDS 2007; 21:589-98.
34. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005; 434:1093-7.
35. Conant MA, Schacker TW, Murphy RL, Gold J, Crutchfield LT, Crooks RJ. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS 2002; 13:12-21.
36. Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 2004; 190:1374-81.
37. Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003; 163:76-80.
38. Sarisky RT, Bacon TH, Boon RJ, et al. Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials. Arch Virol 2003; 148:1757-69.
39. Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 2004; 39(Suppl 5):S248-57.
40. Safrin S, Elbeik T, Phan L, et al. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1994; 38:1246-50.
41. Kost R, Hill E, Tigges M, Straus S. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N Engl J Med 1993; 329:1777-82.